The Globe and Mail
🏢 Globe and Mail Inc. (Woodbridge)
Jul 15, 2026
· 3 min read
AI Analyzed
○ Unverifiable
View full audit trail →
J&J tops estimates on strong medicine sales, raises full-year outlook
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.20 · CENTER
ML v2 (DistilBERT)
-0.244 · LEFT
Ensemble
-0.022 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.008
7,116 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
J&J tops estimates on strong medicine sales, raises full-year outlook
MICHAEL ERMAN
REUTERS
PUBLISHED 45 MINUTES AGO
COMMENTS
SHARE
SAVE FOR LATER
Listen to this article
Learn more about audio
Log in or create a free account to listen to this article.
Johnson & Johnson JNJ-N beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales for heart pumps it picked up in its 2022 acquisition of Abiomed.
J&J also increased its full-year s…
Read full article at The Globe and Mail ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1 + full
Jul 15, 2026